Author response for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13922 ◽

2019 ◽

Vol 22 (4) ◽

pp. 540-548 ◽

Cited By ~ 4

Author(s):

Eiichi Araki ◽

Hirotaka Watada ◽

Yasuko Uchigata ◽

Osamu Tomonaga ◽

Hitomi Fujii ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review3 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Decision letter for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/decision1 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review2 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Decision letter for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/decision1 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study

Journal of Diabetes Investigation ◽

10.1111/jdi.13181 ◽

2020 ◽

Vol 11 (3) ◽

pp. 662-671

Author(s):

Kohei Kaku ◽

Hiroyuki Isaka ◽

Taishi Sakatani ◽

Junko Toyoshima

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Extension ◽

Phase Iii Study

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Oral Oncology ◽

10.1016/j.oraloncology.2017.07.023 ◽

2017 ◽

Vol 73 ◽

pp. 138-146 ◽

Cited By ~ 36

Author(s):

Naomi Kiyota ◽

Yasuhisa Hasegawa ◽

Shunji Takahashi ◽

Tomoya Yokota ◽

Chia-Jui Yen ◽

...

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Iii ◽

Open Label ◽

Asian Patients ◽

Recurrent Squamous Cell Carcinoma ◽

Open Label Phase ◽

Global Population

Design of a precision medicine GAD-alum immunotherapy Phase III clinical trial in Type 1 Diabetes

10.26226/morressier.617c37317c09fc044a975242 ◽

2021 ◽

Author(s):

Ulf Hannelius

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Precision Medicine ◽

Phase Iii ◽

Phase Iii Clinical Trial